Updated: 11:06 a.m. A company that began life in the pharmaceutical sector is venturing forth into devices in its quest to become more of a diversified healthcare company. Chadds Ford, Pennsylvania-based Endo Pharmaceuticals (NASDAQ: ENDP) announced today that the company is buying Minnetonka-based American Medical Systems (NASDAQ:AMMD), a manufacturer of new innovative medical devices focusing […]
Word is out about the identity of the corporate partner NxThera CEO Robert Paulson mentioned last week. It turns out it's American Medical Systems Inc. Minnetonka, Minnesota-based AMS (Nasdaq: AMMD) specializes in medical devices related to pelvic health. Shoreview, Minnesota-based NxThera is developing a thermal vapor prostate treatment -- technology that involves the same area of the body where American Medical Systems' expertise lies.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
GT Urological has raised $4.56 million from the sale of equity, according to documents filed with the Securities and Exchange Commission.
Danish medical device maker Coloplast, which operates its North American headquarters out of Minneapolis, said Friday it bought Mpathy Medical for $30 million.
Tornier Inc. is planning to test the choppy waters of Wall Street with an estimated $205 million initial public offering, according to documents filed with the Securities and Exchange Commission. The orthopedics firm in Edina, Minn., which specializes in devices to treat injuries to extremities and small bones, is the third local medical device company […]
This is the second major divestiture for AMS in the past six months. The Minnetonka-based company sold its Ovion sterilization technology to Mountain View, Calif.-based Conceptus Inc. for $23.6 million last October.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
After discussions with the U.S. Food and Drug Administration, EnteroMedics will apply for approval to conduct another human trial to supplement results from an earlier study, which showed the company's Maestro's device did not perform any better than the control group.